Browse the evidence

GIP receptor antagonism, when combined with GLP-1 receptor agonism, produces superior weight loss and glycemic control compared to GLP-1 receptor agonism alone.

Current research indicates that combining a GIP receptor antagonist with a GLP-1 agonist (like the investigational drug AMG133) leads to greater weight loss and better blood sugar control than using a GLP-1 agonist alone. This benefit is seen in clinical trials with sustained effects, though the exact mechanism of the GIP part's contribution to weight loss is not fully understood.

Tirzepatide, a dual GLP-1 and GIP agonist, significantly reduces Obstructive Sleep Apnea (OSA) severity and body weight in patients with moderate-to-severe OSA and obesity, marking the first FDA-approved pharmacotherapy for this condition.

If you have moderate-to-severe sleep apnea and obesity, tirzepatide is a new, FDA-approved option. It is a once-weekly injection that helps you lose significant weight (16-17%) and reduces your sleep apnea severity (AHI) by 20-24 events per hour. While it may cause temporary stomach issues, it offers a dual benefit for both your sleep and metabolic health.

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) reduce major adverse cardiovascular events (MACE) and cardiovascular death in people with type 2 diabetes and established CVD.

GLP-1 receptor agonists are effective medications that reduce heart attack and stroke risk in people with diabetes or existing heart disease. Access is improving but remains a barrier due to cost.

Tirzepatide produces greater magnitude and faster velocity of weight loss compared to semaglutide in real-world clinical practice.

If you are choosing between Tirzepatide and Semaglutide for weight loss, Tirzepatide is associated with losing more weight (approx 4% more on average) and losing it faster in the first year. This is based on real-world data from over 20,000 patients.

Tirzepatide is associated with a lower prevalence of gastrointestinal and systemic adverse events compared to semaglutide, particularly in high responders.

If you are concerned about side effects like nausea or vomiting, Tirzepatide may be better tolerated than Semaglutide in real-world use, especially if you are a 'high responder' to the drug.

Demographic disparities exist in weight loss response to GLP-1RAs, with White and female patients more likely to be high responders, while Black and Hispanic patients are more likely to be minimal responders.

Be aware that real-world data shows White and female patients are more likely to achieve high weight loss with GLP-1RAs, while Black and Hispanic patients are more likely to have minimal weight loss. This highlights the need for personalized treatment strategies.

Sleeve gastrectomy (SG) induces metabolic changes beyond restriction by reducing ghrelin and increasing GLP-1 and GIP, which stimulates insulin release and delays gastric emptying to improve type 2 diabetes.

If you undergo sleeve gastrectomy, your body's hormone production changes to help control blood sugar and hunger, not just because your stomach is smaller. This metabolic shift is a key reason why type 2 diabetes often improves after this specific surgery.

GLP-1 and GIP receptor agonists reduce the composite incidence of death due to cardiovascular events, nonfatal myocardial infarction, and nonfatal stroke in patients with overweight or obesity.

If you have overweight or obesity, GLP-1 and GIP receptor agonists like semaglutide can reduce your risk of cardiovascular events, including death, heart attack, and stroke.

Semaglutide (2.4 mg weekly) produces significant weight loss (mean -14.9%) in non-diabetic adults with obesity, but this efficacy is accompanied by a high incidence of mild-to-moderate gastrointestinal adverse events (nausea, vomiting, diarrhea) that often lead to treatment discontinuation.

Semaglutide 2.4mg weekly is highly effective for weight loss in non-diabetics, but expect significant gastrointestinal side effects like nausea and vomiting, especially during the first 16 weeks. These side effects are usually mild-to-moderate and transient, but they are the main reason people stop treatment. Medical supervision is crucial to manage these risks and monitor for rare but serious issues like pancreatitis.

A domestic synthetic semaglutide product (Quincenta) demonstrates bioequivalence, comparable pharmacokinetics, and a similar safety/tolerability profile to the reference originator product (Ozempic) in healthy volunteers.

This study confirms that a specific domestic version of semaglutide (Quincenta) behaves in the body similarly to the brand-name version (Ozempic) when given as a single 0.5 mg dose to healthy people. It had no adverse effects and was not immunogenic. This supports the safety and interchangeability of this specific domestic product with the originator.

Semaglutide (2.4 mg/week) achieves high rates of NASH resolution without worsening fibrosis in patients with obesity.

Semaglutide (Ozempic/Wegovy) is a highly effective treatment for resolving NASH. In trials, 59% of patients achieved resolution of the disease without worsening liver scarring, compared to only 17% on placebo. It is administered as a weekly injection.

Four months of supervised endurance exercise training significantly reduces circulating leukocyte counts, particularly effector subtypes (CD4+ Teff, NK cells, neutrophils), in patients with metabolic syndrome.

If you have metabolic syndrome, engaging in supervised endurance exercise for 3-4 months can significantly lower your circulating immune cell counts, specifically those linked to inflammation (effector T cells, NK cells, neutrophils). This benefit occurs regardless of whether you choose moderate continuous training or high-intensity intervals, suggesting consistency and duration are key drivers for immune modulation.

A one-week complete cessation from resistance training (detraining) at the midpoint of a 9-week program does not enhance hypertrophy, power, or endurance compared to continuous training, and significantly reduces strength gains.

If your goal is maximizing strength and size, do not take a full week off from training. This study shows that one week of complete rest during a training block blunts strength gains without improving muscle size. If you are fatigued, consider a 'deload' with reduced volume or intensity rather than complete cessation.

Combining multiple receptor pathways (e.g., GLP-1/GIP, GLP-1/Amylin, or GLP-1/Glucagon) produces synergistic and superior weight loss compared to monotherapy, representing a historical inflection point in obesity pharmacotherapy.

Obesity is a chronic biological disease requiring physiological treatment, not just willpower. Modern combination therapies (targeting GLP-1, GIP, Amylin, or Glucagon receptors) are significantly more effective than older drugs or lifestyle changes alone, achieving 15-24% weight loss in trials. While access and cost are current barriers, these medications are designed to be used alongside lifestyle modifications to overcome biological forces promoting weight gain. Consult a provider about whether combination receptor agonists are appropriate for your health profile.

In patients with type 2 diabetes, initiating tirzepatide (a dual GIP/GLP-1 receptor agonist) results in significantly greater reductions in HbA1c and body weight compared to initiating injectable semaglutide (a GLP-1 receptor agonist) over a 12-month period, regardless of prior GLP-1 RA exposure.

If you have Type 2 Diabetes and are starting a GLP-1 based therapy, choosing tirzepatide over semaglutide is likely to result in better blood sugar control and more significant weight loss over the first year. This benefit holds true whether you have never used these drugs before or have tried semaglutide previously. The trade-off is managing the weekly injection schedule and potential side effects, but the metabolic gains are statistically superior.

Retatrutide increases the rate of gastrointestinal adverse events (nausea, vomiting, constipation) and hypersensitivity reactions compared to placebo, but does not significantly increase serious adverse events.

Be aware that retatrutide is more likely to cause nausea, vomiting, and constipation than a placebo. However, these are typically not 'serious' adverse events, and the drug does not appear to increase the risk of serious health complications or death compared to no treatment. Monitor your symptoms and communicate with your doctor.

Combined exercise and pharmacotherapy significantly reduces systolic and diastolic blood pressure and triglycerides compared to exercise alone, but does not significantly improve fasting glucose, HDL, or LDL.

While adding medication to exercise improves blood pressure and triglycerides, it may not significantly improve fasting glucose or cholesterol levels (HDL/LDL) compared to medication alone. Focus on the weight loss and blood pressure benefits.

SGLT2 inhibitors reduce blood pressure and body weight in patients with Type 2 Diabetes.

SGLT2 inhibitors can help you lose a small amount of weight (about 1.7 kg or 2.4%) and lower your blood pressure. This is achieved through osmotic diuresis and reduced body fat mass. These effects contribute to overall cardiovascular and renal health.

GLP-1 receptor agonists (liraglutide, semaglutide, tirzepatide) induce significant weight loss and provide renoprotective effects (reduced albuminuria and slower eGFR decline) in adults with chronic kidney disease (CKD), with efficacy potentially maintained or enhanced in lower eGFR subgroups.

If you have CKD and obesity, newer GLP-1 medications (like semaglutide or tirzepatide) are highly effective for weight loss and may actually protect your kidneys by reducing protein in urine and slowing kidney function decline. Unlike diet and exercise alone, which often fail long-term, these drugs target the hormonal drivers of obesity. Start with a low dose and increase slowly to avoid stomach issues, and stay hydrated to protect your kidneys.

GLP-1 receptor agonists (e.g., liraglutide, semaglutide) resolve MASH histology primarily through substantial weight loss and improved insulin resistance, rather than direct hepatocyte effects.

GLP-1 agonists like semaglutide and liraglutide are effective treatments for MASH, but their primary benefit comes from the weight loss and metabolic improvements they induce, not a direct 'liver cure.' Expect significant weight loss (often 10-15%+), but also manage expectations regarding side effects like nausea, which are common initially. These drugs resolve MASH in a majority of patients but may not reverse advanced fibrosis as effectively. Consult a specialist to determine if the benefits outweigh the burden of injection and side effects for your specific liver stage.

GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) produce significant real-world weight loss, but effectiveness is substantially lower than in clinical trials due to high discontinuation rates (20-50%) and suboptimal dosing in routine care.

GLP-1 medications like semaglutide and tirzepatide are highly effective for weight loss, but their real-world success depends entirely on sticking with them. Many people stop early due to side effects or cost, leading to less weight loss than seen in trials. To get the best results, you must manage side effects (which often fade) and ensure you can afford the medication long-term. If you adhere to the full dose and stay on the drug, your weight loss can match what is seen in clinical trials.

Obesity increases the risk of kidney stones (nephrolithiasis) through mechanisms including lower urine pH, increased urinary oxalate, uric acid, and sodium excretion, as well as insulin resistance.

Obesity increases your risk of kidney stones by changing your urine chemistry. To protect your kidneys, stay hydrated, limit excessive protein and sodium intake, and manage your weight through balanced nutrition.

High intake of refined carbohydrates, particularly white rice, is strongly associated with an increased risk of metabolic syndrome and type 2 diabetes in Asian populations, whereas complex carbohydrates (brown rice, legumes) are protective.

Not all carbs are created equal. White rice, white bread, and sugary drinks spike your blood sugar and insulin, driving up your risk for diabetes and metabolic syndrome. Switch to complex carbohydrates like brown rice, whole wheat, legumes, and vegetables. These 'good carbs' provide fiber and nutrients that protect against insulin resistance.

Obesity increases the risk and severity of periodontitis through systemic inflammation and adipokine release, creating a bidirectional relationship where higher BMI correlates with poorer periodontal outcomes.

Higher body weight is biologically linked to more severe gum disease due to inflammation. If you are overweight, you are at higher risk for gum bone loss. Managing weight and treating gum disease are interconnected parts of your overall health.